Syndax PharmaceuticalsNASDAQ: SNDX

BOSTON, June 10, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: “PYXS”), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today announced the appointment of Michael A. Metzger to its Board of Directors, effective June 10, 2024. Mr. Metzger has over 25 years of experience in the biopharmaceutical sector, currently serving as Chief Executive Officer and as a member of the Board of Directors of Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX) since 2015.

WALTHAM, Mass. , June 3, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that on June 1, 2024 the Company granted inducement awards to purchase up to 499,200 shares of common stock to fifty-three new employees under the Company's 2023 Inducement Plan.

Syndax Pharmaceuticals, a biopharmaceutical company focused on developing cancer therapies, will release its first quarter financial results and business update on May 8, 2024.

Syndax Pharmaceuticals, Inc. (SNDX) Q4 2023 Earnings Call Transcript

Syndax (SNDX) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Syndax Pharmaceuticals Inc (SNDX) Q3 2023 Earnings Call Transcript

Syndax Pharmaceuticals, Inc. reported positive results from its phase 1/2 trial using revumenib to treat relapsed/refractory leukemia patients. The trial met its primary endpoint with a complete remission rate of 23%, significantly higher than the current standard of care. It is expected that an NDA of revumenib for AML is expected before end of 2023; it is also being evaluated in other patient populations which could expand its potential.

Syndax Pharmaceuticals (NASDAQ:SNDX) Inc (Syndax Pharmaceuticals (NASDAQ:SNDX)) stock was on the back foot on Monday, after reporting results from a leukaemia drug trial which met its primary endpoint. "We are thrilled to report positive results for revumenib in KMT2Ar acute leukaemia that demonstrate the utility of its practice-changing clinical profile and highlight revumenib's potential as a first- and best-in-class agent," chief executive Michael Metzger said.

Syndax is making strides in the adoption of entinostat, a cancer therapeutic used in combination with immune checkpoint therapies. Syndax reported an increase in operating expenses in Q2 2023, but remains financially stable with cash reserves of $418.3 million. Syndax has two leading candidates in its drug pipeline, revumenib and axatilimab, which show promise in treating acute leukemia and chronic graft-versus-host disease (cGVHD) respectively.